Longeveron shares are trading lower. The company announced the completion of an investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for Hypoplastic Left Heart Syndrome.
Portfolio Pulse from Benzinga Newsdesk
Longeveron shares are trading lower following the announcement of the completion of an investigator meeting for ELPIS II, the ongoing Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for Hypoplastic Left Heart Syndrome.
June 11, 2024 | 4:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Longeveron shares are trading lower after the company announced the completion of an investigator meeting for ELPIS II, a Phase 2b clinical trial for Lomecel-B in treating Hypoplastic Left Heart Syndrome.
The decline in Longeveron's share price is likely due to investor concerns or uncertainty surrounding the progress and outcomes of the ELPIS II clinical trial. The completion of the investigator meeting may not have provided sufficient positive updates to boost investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100